(Q38160271)

30 August 2017

Emerging drugs for urothelial carcinoma (English)

1 reference

30 August 2017

Benjamin A Gartrell

1

1 reference

PubMed ID

24195728

30 August 2017

Guru Sonpavde

series ordinal

2

1 reference

PubMed ID

24195728

30 August 2017

language of work or name

English

0 references

publication date

6 November 2013

1 reference

Expert Opinion on Emerging Drugs

30 August 2017

1 reference

30 August 2017

18

1 reference

30 August 2017

477-494

1 reference

30 August 2017

4

1 reference

30 August 2017

Cancer statistics, 2013

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Natural history of surgically treated bladder carcinoma with extravesical tumor extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer who are unfit for cisplatin-based chemotherapy: EORTC study 30986

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of paclitaxel in pretreated patients with locally advanced/metastatic cancer of the bladder and ureter

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Molecular pathways of urothelial development and bladder tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Chromosomal changes in uroepithelial carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Identification of nine genomic regions of amplification in urothelial carcinoma, correlation with stage, and potential prognostic and therapeutic value.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Common genetic variants in the PSCA gene influence gene expression and bladder cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Effect of vascular endothelial growth factor and its receptor inhibitor on proliferation and invasion in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of gemcitabine, carboplatin, and bevacizumab in patients with advanced unresectable or metastatic urothelial cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Sunitinib malate is active against human urothelial carcinoma and enhances the activity of cisplatin in a preclinical model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of sunitinib in patients with metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Gemcitabine, Cisplatin, and sunitinib for metastatic urothelial carcinoma and as preoperative therapy for muscle-invasive bladder cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Combined treatment with pazopanib and vinflunine in patients with advanced urothelial carcinoma refractory after first-line therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of Aflibercept (VEGF-Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer Consortium Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

High epidermal growth factor receptor immunohistochemical expression in urothelial carcinoma of the bladder is not associated with EGFR mutations in exons 19 and 21: a study using formalin-fixed, paraffin-embedded archival tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

AdCD40L immunogene therapy for bladder carcinoma--the first phase I/IIa trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Cancer-testis antigens: expression and correlation with survival in human urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of everolimus in metastatic urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Profiling bladder cancer using targeted antibody arrays

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: a comparison with p53 nuclear accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

The role of heat shock proteins in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Dasatinib is preclinically active against Src-overexpressing human transitional cell carcinoma of the urothelium with activated Src signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Advocates' perspective: neoadjuvant chemotherapy for breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Expression of estrogen receptors-alpha and -beta in bladder cancer cell lines and human bladder tumor tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

AEZS-108 : a targeted cytotoxic analog of LHRH for the treatment of cancers positive for LHRH receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A phase II study of PS-341 (Bortezomib) in advanced or metastatic urothelial cancer. A trial of the Princess Margaret Hospital and University of Chicago phase II consortia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A phase II trial of neoadjuvant nab-paclitaxel, carboplatin, and gemcitabine (ACaG) in patients with locally advanced carcinoma of the bladder

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Cisplatin: mode of cytotoxic action and molecular basis of resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

BRCA1 mRNA expression and outcome to neoadjuvant cisplatin-based chemotherapy in bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

URINARY VASCULAR ENDOTHELIAL GROWTH FACTOR AND ITS CORRELATION WITH BLADDER CANCER RECURRENCE RATES

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

Treatment of Muscle Invasive Bladder Cancer: Evidence From the National Cancer Database, 2003 to 2007

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728214.2013.853741

10.1517/14728214.2013.853741

21 January 2018

Identifiers

DOI

1 reference

30 August 2017

1 reference

PubMed ID

24195728